Literature DB >> 8017286

Metabolic risk factors for atherosclerosis in heart transplant recipients.

M S Kemna1, H A Valantine, S A Hunt, J S Schroeder, Y D Chen, G M Reaven.   

Abstract

Development of coronary artery disease (CAD) in the cardiac allograft limits long-term survival after heart transplantation. Previous studies, focusing on lipoprotein metabolism, have paid little attention to changes in glucose and insulin metabolism that increase the risk of CAD in these patients. To address this issue, plasma glucose and insulin responses to an oral glucose load and lipid and lipoprotein concentrations were measured in male normal volunteers (n = 40) and cardiac transplant recipients with pretransplant diagnoses of either idiopathic cardiomyopathy (n = 24) or ischemic heart disease (n = 28), matched for age and body mass index. Patients with a pretransplant diagnosis of ischemic heart disease had higher plasma glucose and insulin concentrations in response to oral glucose as well as higher fasting plasma triglyceride, cholesterol, and low-density lipoprotein cholesterol concentrations than did the control group (p < 0.005 to p < 0.001). In addition, high-density lipoprotein cholesterol concentrations were lower and the ratio of cholesterol to high-density lipoprotein cholesterol higher than control values in those with a pretransplant diagnosis of ischemic heart disease (p < 0.001). Values for almost all variables were intermediate in patients with a pretransplant diagnosis of idiopathic cardiomyopathy and in most instances were significantly different from both. Thus, male cardiac transplant recipients are dyslipidemic, relatively glucose intolerant, and hyperinsulinemic compared to normal volunteers. These changes, observed in patients with a pretransplant diagnosis of either ischemic heart disease or idiopathic cardiomyopathy, emphasize the important role of immunosuppression in the development of metabolic risk factors for CAD in these individuals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8017286     DOI: 10.1016/0002-8703(94)90011-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

Review 1.  Update on pediatric heart transplantation. Long-term complications.

Authors:  R J Gajarski; D L Kearney; J K Price; S W Denfield
Journal:  Tex Heart Inst J       Date:  1997

Review 2.  Cardiac allograft vasculopathy: a review.

Authors:  Danny Ramzy; Vivek Rao; Julie Brahm; Santiago Miriuka; Diego Delgado; Heather J Ross
Journal:  Can J Surg       Date:  2005-08       Impact factor: 2.089

Review 3.  The challenge of rejection and cardiac allograft vasculopathy.

Authors:  W G Cotts; M R Johnson
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

Review 4.  Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets.

Authors:  Luciano Potena; Hannah A Valantine
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

5.  Multicenter assessment of coronary allograft vasculopathy by intravascular ultrasound-derived analysis of plaque composition.

Authors:  Giovanna Sarno; Amir Lerman; Jang-Ho Bae; Christoph Schukro; Dietmar Glogar; Pauliina M Margolis; Marc Goethals; Sofie Verstreken; Jozef Bartunek; Andreas Koenig; William Wijns; Marc Vanderheyden
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-02

Review 6.  Management of hyperlipidaemia associated with heart transplantation.

Authors:  Klaus Wenke
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Percutaneous coronary intervention versus coronary artery bypass grafting in heart transplant recipients with coronary allograft vasculopathy: a systematic review and meta-analysis of 1,520 patients.

Authors:  Jessica G Y Luc; Jae Hwan Choi; Syed-Saif Abbas Rizvi; Kevin Phan; Ester Moncho Escrivà; Sinal Patel; Gordon R Reeves; Andrew J Boyle; John W Entwistle; Rohinton J Morris; H Todd Massey; Vakhtang Tchantchaleishvili
Journal:  Ann Cardiothorac Surg       Date:  2018-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.